Celldex Therapeutics, Inc. (CLDX) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Celldex Therapeutics, Inc. (CLDX) closed at USD 27.84 on 2026-10-14, a change of +2.9 % over the past year, with a market capitalization of USD 2.27B.
Celldex Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 27.84 |
| 2026-10-13 | 28.25 |
| 2026-10-12 | 29.43 |
| 2026-10-09 | 29.89 |
| 2026-10-08 | 29.30 |
| 2026-10-07 | 30.43 |
| 2026-10-06 | 31.01 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Celldex Therapeutics, Inc. key figures
- Previous close
- USD 27.84 (2026-10-14)
- 1-year change
- +2.9 %
- Market cap
- USD 2.27B
- Enterprise value
- USD 1.56B
- P/E ratio (trailing)
- -6.49
- P/E ratio (forward)
- -6.83
- EPS (trailing)
- -4.46
- EPS (forward)
- -4.24
- PEG ratio
- n/a
- Price to book
- 3.18
- Revenue growth
- -97 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 6.00
- Employees
- 198
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Celldex Therapeutics, Inc. and compare it with other stocks.
Analyze CLDXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Celldex Therapeutics, Inc. shares.